AbbVie to Showcase Breadth of Oncology Portfolio and Pipeline at the 2021 ASCO and EHA Annual Congresses
ABBVie will present results from 43 abstracts across 12 types of cancer during the upcoming virtual American Society of Clinical Oncology Annual Meeting and the virtual European Hematology Association congress . “We are advancing discovery and innovation to improve on the standards of care for blood cancer treatment,” said Mohamed Zaki M.D., Ph.D., vice president and global head of oncology development, AbbVie. “We …
– ABBVie (NYSE: ABBV) will present results from 43 abstracts across 12 types of cancer during the upcoming virtual American Society of Clinical Oncology (ASCO) Annual Meeting ( June 4-8 ) and the virtual European Hematology Association (EHA) congress ( June 9-17 ).
You are reading 1 of 15 free-access articles allowed for 30 days
Dr Amjad Hayat, consultant haematologist, Galway University Hospital and the Advanced Therapies and Cancer Group, School of Medicine, NUI Galway. Photo: Aengus McMahon
NUI Galway leads global clinical trial to improve health outcomes for cancer patients
Researchers looking to recruit newly diagnosed patients with Mantle Cell Lymphoma
A leading haematologist at Galway University Hospital and the Advanced Therapies and Cancer Group at School of Medicine in NUI Galway are looking at improving health outcomes for patients with Mantle Cell Lymphoma by conducting a clinical trial of a new treatment drug which aims to improve survival rates.
Jubilant Therapeutics Presents Preclinical Data on its Brain Penetrant PRMT5 Inhibitor and Small Molecule PD-L1 Inhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2021
- JBI-1527, a potent, selective oral inhibitor of PD-L1 exhibited T-cell restoration and immune-mediated tumor growth suppression
- Data support the further development of PRMT5 inhibitor JBI-778 and PD-L1 inhibitor JBI-1527 for the treatment of unmet need in oncology
BEDMINSTER, N.J., April 10, 2021 /PRNewswire/ Jubilant Therapeutics Inc., a biopharmaceutical company advancing oral, small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, today announced that preclinical data from two programs evaluating the company s PRMT5 inhibitor and PD-L1 inhibitor as anti-cancer agents, will be presented today in a poster session at the American Association for Cancer Research (AACR) 2021 Annual Meeting taking place virtually from April 10-15, 2021.